Most pharma commercial teams learn about competitive market events the same way everyone else does: someone sends a link in Slack, or a brand team member spots something at a congress. Life sciences market intelligence built this way is reactive by definition. By the time the alert reaches the insights team, the decision window has narrowed. The ZoomRx Market Intelligence module inside Sagan Agents is designed to change that, replacing reactive scanning with a continuously updated, always-on intelligence layer that arrives before your first meeting of the day.
Generic market intelligence tools aggregate public data: clinical trial registrations, press releases, earnings transcripts. That content is available to everyone, which means any advantage it provides is temporary. The more meaningful advantage comes from proprietary data that cannot be licensed or replicated — the kind that has been built one study at a time over years of primary research.
ZoomRx Market Intelligence combines two distinct layers. The first is continuously updated external signal monitoring: clinical intelligence, commercial intelligence, regulatory actions, and HCP and Patient level behavioral data, refreshed daily across all source types with full narrative context preserved rather than reduced to structured rows. The second is 15 years of ZoomRx's proprietary benchmarking data — more than 700 million datapoints covering brand positioning, competitive landscapes, HCP-patient conversations, media tracking, and sales force benchmarks across all major therapeutic areas.
The signal coverage spans four primary categories.
Market alerts notify the insights team immediately when something material changes in the competitive landscape. A competitor label expansion, a Phase 2 readout from a European congress, a shift in physician sentiment on a key social channel — all surface overnight and are waiting with context already attached when the team opens the platform.
Every alert arrives pre-loaded with context from the client's Data Archive. When a competitor label expansion is flagged, the platform has already pulled the last three ATU waves showing that competitor's trajectory, the most recent message testing study on their efficacy claims, and a claims-based view of actual prescribing trends in the relevant segment. Every source is cited and linked through a paperclip navigation system that lets users drill to the original study, the original slide, or the underlying data extract.
This is the architectural difference between market monitoring and market intelligence. Monitoring tells you what happened. Intelligence tells you what it means in the context of your brand, your data, and your competitive history. ZoomRx Market Intelligence is designed to deliver the second, not just the first.
One of the most distinctive assets inside ZoomRx Market Intelligence is a library of more than 1,500 real physician-patient interaction transcripts — actual clinical conversations showing how treatment decisions get made at the point of care. This is not synthesized or simulated content. It is ground-truth behavioral data from real HCP-patient interactions, accumulated over years of primary research, and not available from any other vendor.
These transcripts surface behavioral patterns that survey data alone cannot capture: the language physicians use when explaining treatment choices to patients, the questions patients ask that shift prescribing decisions, the friction points where clinical evidence and patient preference diverge. That behavioral signal is one of the calibration inputs for Market Simulator, Sagan Agents' market simulation module, which builds on this foundation to model how market events propagate through physician networks.
ZoomRx Market Intelligence is not a static dataset. The archive grows richer as new research flows in automatically from every ZoomRx engagement. A brand tracker commissioned for one therapeutic area adds benchmark context for adjacent indications. A message testing study for one brand enriches the competitive landscape understanding for a portfolio brand in the same class. The intelligence compounds because the architecture is designed to compound.
For pharma commercial teams navigating shrinking budgets and accelerating competitive dynamics, the alternative to a continuously updated pharmaceutical benchmarking data system is constant manual scanning, reactive briefings, and decisions made with stale context. That model is showing its limits. To see how ZoomRx Market Intelligence fits into your commercial operations, explore Sagan Agents or reach out directly.